Health12 min

CBD Drinks as an Alcohol Alternative: What the Science Says

CBD beverages are the fastest-growing alcohol alternative in the UK. The science says the bioavailability is dismal and placebo does most of the work. But as a substitute for alcohol, the data says they're succeeding anyway.

In July 2024, research from KAM Insight and High & Dry found that nearly one in five UK adults have now tried a CBD-infused drink, with a further 28% expressing interest. The report, covered by the International Food & Drink Event (IFE), found that 40% of users said their alcohol intake decreased when they used these alternative mood-altering substances. [KAM Insight / High & Dry (Jul 2024)]

This is part of a much larger pattern. The UK low- and no-alcohol market grew 25% year-on-year in 2023, outpacing nearly every other beverage category. The global zero-alcohol beverage market is projected to reach $4.1 billion by 2032, growing at a compound annual rate of 13.7%. Brands like TRIP, which infuses CBD into sparkling waters, are now listed in major supermarkets and pub chains nationwide. [Grand View Research (2024)]

But there is a gap between the marketing and the pharmacology that deserves honest scrutiny. CBD drinks are not what they appear to be — and the science is clear that the hype has run ahead of the chemistry.

The First-Pass Problem

When you swallow a CBD-infused drink, the cannabinoid enters your digestive system and is carried to the liver via the portal vein before it ever reaches systemic circulation. In the liver, cytochrome P450 enzymes — primarily CYP2C19 and CYP3A4 — extensively metabolise CBD, breaking it down into metabolites before it can enter the bloodstream in meaningful concentrations. [Beers et al. (2021), Drug Metab Dispos]

This is called first-pass hepatic metabolism, and it is brutal for oral CBD:

Oral bioavailability of CBD (fasting): ~6%. Perucca and Bialer (2020) in CNS Drugs confirmed that 94% of an orally ingested dose never reaches systemic circulation under fasting conditions. Co-administration with a high-fat meal increases this roughly fourfold to ~24%, but this is rarely practical for a commercial canned beverage. [Perucca & Bialer (2020), CNS Drugs]
Inhaled (vaped/smoked) bioavailability: 11–45%. CBD absorbed through the lungs bypasses first-pass metabolism entirely, delivering substantially more CBD per milligram. [Chayasirisobhon (2020), Perm J]
Sublingual oils: Absorption through the oral mucosa partially bypasses the liver, but results vary widely by formulation and technique. [Yau et al. (2023), Pharm Res]

Oral CBD bioavailability is approximately 6%. That means 94% of the CBD in your drink never reaches your bloodstream. Inhaled CBD delivers 11–45%.

Beers et al. (2021) in Drug Metabolism and Disposition showed that CYP2C19 and CYP2C9 convert CBD to its primary active metabolite 7-hydroxy-CBD, while CYP3A4 drives overall metabolic clearance. A 2023 clinical study by Bansal et al. in Clinical Pharmacology & Therapeutics demonstrated the real-world potency of this interaction: when CBD was co-administered with omeprazole (a CYP2C19 substrate), omeprazole exposure increased by 207% — confirming that the liver aggressively processes oral CBD before it can act systemically. [Bansal et al. (2023), Clin Pharm Ther]

Nanoemulsions Don't Solve It

Many premium CBD drinks now use nanoemulsion technology — breaking CBD oil droplets to nanoparticle size to improve water solubility. ElSohly et al. (2023) in Medical Cannabis and Cannabinoids tested an UltraShear nanoemulsion and found oral bioavailability of 18.6% at 6 hours and 25.4% at 24 hours — roughly 3–4x improvement over standard oral solutions. [ElSohly et al. (2023), Med Cannabis Cannabinoids]

This is better — but it is still below the lower bound of inhalation. And the CBD that survives nanoemulsion still faces the liver. Nanoemulsion simply delivers more CBD to the hepatic enzymes; it does not bypass them. A 2025 study by Sandmeier et al. in Colloids and Surfaces B: Biointerfaces found that even advanced self-emulsifying drug delivery systems (SEDDS) achieved only 3.8% bioavailability — comparable to the pharmaceutical-grade oral solution Epidiolex at 3.4%. [Sandmeier et al. (2025), Colloids Surf B Biointerfaces]

The Dose That Isn't There

Most commercial UK CBD drinks contain 10–30 mg of CBD per can. Clinical trials for anxiety — the most common reason consumers cite for using CBD — typically use doses of 300–600 mg. Bergamaschi et al. (2011) in Neuropsychopharmacology found that 400 mg of oral CBD significantly reduced anxiety in social phobia patients during a public speaking test — but only at that dose, and only in a controlled setting. [Bergamaschi et al. (2011), Neuropsychopharmacology]

At 10–30 mg per can with ~6% bioavailability, a single CBD drink delivers roughly 0.6–1.8 mg of bioavailable CBD. This is two to three orders of magnitude below the doses established as therapeutically effective in peer-reviewed trials. Yau et al. (2023) in Pharmaceutical Research systematically ranked routes of administration for CBD in brain disorders — "intranasal and inhalation > sublingual, buccal, transdermal > oral, injection" — placing beverages at the bottom of the efficacy hierarchy. [Yau et al. (2023), Pharm Res]

The Placebo That Pays the Bills

The 2024 IFE report says 70% of psychotropic-curious users drink CBD beverages to "help them relax" and 60% for "relief from anxiety." These are the subjective endpoints where placebo effects are strongest. A landmark 2019 systematic review by Chesney et al. in The Lancet Psychiatry examined 24 randomised controlled trials of cannabinoids for psychiatric conditions and found that the placebo response accounted for 30–50% of reported symptom improvement across all studies. [Chesney et al. (2019), Lancet Psychiatry]

When you factor in the expectation effect (you paid £4 for a "calm" drink — your brain will deliver), the ritual of sipping a cold beverage, sensory branding (tall cans, pastel packaging, words like "zen"), and conditioned responses (associating drinking with a shift in mental state), the CBD content itself becomes a minor contributor at best. A 2022 review by Potschka et al. in The Veterinary Journal on CBD for canine epilepsy found that one clinical trial "failed to confirm a difference in response rates between the CBD group and the placebo group" — even in a condition as objective as seizure frequency. For subjective anxiety, the placebo signal would be expected to be far stronger. [Potschka et al. (2022), Vet J]

The placebo response in cannabinoid trials accounts for 30–50% of symptom improvement — strongest for subjective endpoints like anxiety and relaxation.

Why This Is Still a Public Health Win

None of this is an argument against CBD drinks. It is an argument for honest framing. If someone buys a can expecting pharmaceutical-grade anxiolysis from 15 mg of CBD, they will be disappointed by the chemistry. But if they buy it instead of a pint of lager, the entire calculus changes.

The WHO's 2024 Global Status Report on Alcohol confirmed that alcohol causes approximately 2.6 million deaths per year worldwide. Alcohol is a Group 1 carcinogen — the same IARC classification as asbestos and tobacco — linked to breast, liver, head and neck, oesophageal, and colorectal cancers. In 2019, 4.4% of all cancers diagnosed globally and 401,000 cancer deaths were attributed to alcohol. The WHO is unequivocal: there is no risk-free dose of alcohol. [WHO (2024)]

Against this backdrop, a drink that contains 25 mg of CBD (of which ~1.5 mg reaches your bloodstream), zero alcohol, and a plausible placebo effect is not a failure. It is a massive public health win. The 40% of users who reported drinking less alcohol when CBD alternatives are available is the number that matters. Whether the CBD is doing the work or the placebo, ritual, and conscious choice are driving the effect is almost irrelevant from a public health standpoint — the outcome (reduced alcohol consumption) is unambiguously positive.

The alcohol industry itself recognises this shift. Ten of the world's largest alcohol companies already have cannabis investments: Constellation invested in Canopy Growth; Molson Coors partnered with Hydropothecary; Heineken launched THC-infused Hifi Hops through Lagunitas. The industry is hedging against its own product. CBD drinks, for all their pharmacokinetic limitations, are part of the post-alcohol ecosystem — not because they deliver CBD efficiently (they don't), but because they offer a socially substitutable behaviour. [KAM Insight / High & Dry (Jul 2024)]

The Bottom Line

CBD drinks are pharmacokinetically underwhelming. Oral bioavailability is ~6% (improving to 18–25% with nanoemulsion); most drinks contain 10–30 mg, delivering less than 2 mg systemically; and placebo accounts for up to half the subjective effects. But their real purpose is not pharmaceutical-grade CBD delivery — it is giving people a drink that looks, feels, and functions socially like alcohol, without the carcinogen.

On that metric, the data is unequivocal: the zero-alcohol market is growing at 13.7% annually, 40% of CBD drink users reduce their alcohol intake, and the cultural momentum is accelerating. The chemistry may be imperfect, but the outcome is exactly what the evidence demands.

For the broader data on how cannabis compares to alcohol across every measurable harm metric, see our Substance Matrix and the full Harm Matrix. For the cultural shift driving the decline in drinking, read The Cultural Shift: 24% of UK Adults Now Teetotal.